Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases.
Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders C, Carrillo J, Chalasani P, Kabos P, Puhalla S, Tkaczuk K, Garcia AA, Ahluwalia MS, Wefel JS, Lakhani N, Ibrahim N. Kumthekar P, et al. Among authors: tkaczuk k. Clin Cancer Res. 2020 Jun 15;26(12):2789-2799. doi: 10.1158/1078-0432.CCR-19-3258. Epub 2020 Jan 22. Clin Cancer Res. 2020. PMID: 31969331 Clinical Trial.
Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Nabholtz JM, Cantin J, Chang J, Guevin R, Patel R, Tkaczuk K, Vodvarka P, Lindsay MA, Reese D, Riva A, Mackey J. Nabholtz JM, et al. Among authors: tkaczuk k. Clin Breast Cancer. 2002 Oct;3(4):268-75. doi: 10.3816/CBC.2002.n.030. Clin Breast Cancer. 2002. PMID: 12425755 Clinical Trial.
Identification of Functional Immune Biomarkers in Breast Cancer Patients.
Derakhshandeh R, Zhu Y, Li J, Hester D, Younis R, Koka R, Jones LP, Sun W, Goloubeva O, Tkaczuk K, Bates J, Reader J, Webb TJ. Derakhshandeh R, et al. Among authors: tkaczuk k. Int J Mol Sci. 2024 Nov 16;25(22):12309. doi: 10.3390/ijms252212309. Int J Mol Sci. 2024. PMID: 39596374 Free PMC article.
Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment.
O'Connell BC, Hubbard C, Zizlsperger N, Fitzgerald D, Kutok JL, Varner J, Ilaria R Jr, Cobleigh MA, Juric D, Tkaczuk KHR, Elias A, Lee A, Dakhil S, Hamilton E, Soliman H, Peluso S. O'Connell BC, et al. Among authors: tkaczuk khr. J Immunother Cancer. 2024 Aug 30;12(8):e009160. doi: 10.1136/jitc-2024-009160. J Immunother Cancer. 2024. PMID: 39214650 Free PMC article. Clinical Trial.
A Prospective Trial of Single-Fraction Radiation to the Tumor Bed with a Novel Breast-Specific Stereotactic Radiation Therapy Device: The GammaPod.
Nichols EM, Bentzen SM, Milburn M, Kesmodel SB, Bellavance E, Becker SJ, Mutaf Y, Tkaczuk K, Rosenblatt P, Feigenberg SJ. Nichols EM, et al. Among authors: tkaczuk k. Adv Radiat Oncol. 2024 Jan 6;9(4):101398. doi: 10.1016/j.adro.2023.101398. eCollection 2024 Apr. Adv Radiat Oncol. 2024. PMID: 38778822 Free PMC article.
109 results